Notably, our preclinical data indicates that the SALL4-expressing lung cancer cells were more sensitive to the histone deacetylase inhibitor (HDACi) entinostat (MS-275) treatment, suggesting that lung cancer patients with SALL4 overexpression may benefit from treatment with entinostat. The gene discussed is SALL4; the disease is lung carcinoma.